Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05774899 · ClinicalTrials.gov registry record · Phase 1
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
A Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, sponsored by Glenn J. Hanna.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05774899: Recruiting Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, sponsored by Glenn J. Hanna.
NCT05774899 is a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma that is actively recruiting participants, run by Glenn J. Hanna. The registered enrollment target is 32 participants, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05774899, a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, is actively recruiting participants, sponsored by Glenn J. Hanna.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-103 (an oral NOTCH pathway inhibitor) * Abemaciclib (CDK4/6 inhibitor) * Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))
Primary Outcome
Progression-Free Survival (PFS) is defined as the time from study registration to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Median PFS will be estimated via the Kaplan-Meier method to estimate all time-to-event endpoints with corresponding 95% confidence intervals (CI) for the median or time-specific event time
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Lenvatinib
- DRUG CB-103
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
What NCT05774899 shows while recruiting
NCT05774899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Abemaciclib is the first listed.
NCT05774899 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05774899 about?
NCT05774899 is a clinical study titled "CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC". The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-103 (an oral NOTCH pat...
What is the current status of trial NCT05774899?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2023-06-01. Estimated completion is 2027-06-01.
What conditions does trial NCT05774899 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT05774899?
The interventions under investigation include: Abemaciclib (DRUG), Lenvatinib (DRUG), CB-103 (DRUG).
Who is sponsoring clinical trial NCT05774899?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05774899 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05774899's enrollment target sits among peer trials
32 15th of 16 higher than 1 of 16 other Adenoid Cystic Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenoid Cystic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
RECRUITING · Phase 1
-
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RECRUITING · Phase 1
-
A Study of XMT-1660 in Participants With Solid Tumors
RECRUITING · Phase 1
-
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI